The medication is commonly used to address symptoms that create noticeable physiological strain arising from specific parasitic infections. Its primary uses include the treatment and control of strongyloidiasis (threadworm) and onchocerciasis (river blindness), among others. This medicine is applied across domains where additional symptomatic support is needed, and supports patients during episodes of heightened discomfort.

---

Symptomatic Relief and Benefits

This medicine is commonly used to help with symptoms related to inflammatory or irritative states on the skin, such as intense itching, persistent rashes, and nodule formation. It also helps manage internal symptoms like abdominal pain, cramping, and chronic diarrhea caused by internal worm infections.

The therapeutic benefit is relevant for easing symptoms that interfere with daily functioning and may be part of symptomatic management in situations where conditions present with systemic discomfort, particularly those affecting the eyes and vision. The medication may assist with maintaining functional stability and supports general well-being during symptomatic phases, contributing to improved comfort during periods of heightened symptoms.

“The medication helps address symptom clusters that may become intense or disruptive, offering symptomatic relief to help patients cope more steadily with symptom fluctuations.”

Summary of Symptom Relief Domains

This medication is relevant for easing symptoms that create noticeable physiological strain across therapeutic areas, including symptomatic relief for parasite-related skin manifestations and systemic digestive discomfort.

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Ivomec 0.27%?

The population eligibility for Ivermectin (the active ingredient in this solution) is strictly defined by government regulatory agencies based on patient characteristics and existing conditions. Eligibility rules determine who may use the medicine and who is formally prohibited from use.

Contraindications and Minimum Eligibility

Classification	Status & Official Constraint
Absolute Contraindication	Patients with a known hypersensitivity to Ivermectin or any component of the formulation.
Minimum Weight Threshold	Contraindicated in children weighing less than 15 kilograms (33 lbs), as safety and effectiveness are not established in this group.
Prior Adverse Reaction	Re-treatment is prohibited if the patient previously developed a Severe Cutaneous Adverse Reaction (SCAR) following Ivermectin use.

Conditional Use and Restricted Populations

Population Group	Eligibility Status & Restriction
Pregnancy	Not recommended; use is only permitted when the potential benefit is strictly deemed to outweigh the potential risk.
Lactation	Not recommended; Ivermectin is excreted in human milk. Use is conditional on the risk of delayed maternal treatment.
Co-infection (Loa loa)	Conditional use requiring caution due to increased risk of serious reactions, including encephalopathy.
Organ Impairment	Caution is advised for patients with hepatic or renal impairment as pharmacokinetics have not been adequately studied in these groups.

Older adults should also be treated cautiously, reflecting the greater frequency of decreased organ function.

Interactions with other medicines and products

The official regulatory profile for Ivermectin, the active ingredient in Ivomec 0.27%, defines interaction patterns based on specific pharmacokinetic constraints and documented co-administration reports. The information below reflects the findings of government authorities regarding interaction significance and required constraints.

---

Documented Interaction Patterns

Interaction Type	Interacting Substance	Official Regulatory Finding
Exposure Modification	Warfarin	Co-administration is associated with rare post-marketing reports of increased International Normalized Ratio (INR).
Metabolic Potential	Major CYP Enzymes	Ivermectin is primarily metabolized by CYP3A4, but regulatory data indicate it does not significantly inhibit the activity of major CYP enzymes (CYP3A4, 2D6, 2C9, 1A2, 2E1).
Administration Timing	Food	Administration must be separated from meals (on an empty stomach), as food is documented to increase the systemic absorption of Ivermectin.
Population-Specific	Loa loa Co-infection	Patients co-infected with Loa loa face a caution regarding the risk of serious or fatal encephalopathy following treatment.

---

Profile Summary

The interaction structure is defined by the necessary timing rule to manage absorption (must be taken on an empty stomach) and a specific caution concerning the anticoagulant warfarin, which may modify the patient's bleeding risk profile. Official regulatory documents confirm that Ivermectin's limited ability to inhibit major CYP enzymes suggests a low potential for enzyme-mediated interactions with many other medicines. These findings establish the boundaries for co-administration as recognized by regulatory bodies.

Molecular Mechanism: Chloride Channel Activation

Ivermectin acts as a positive allosteric modulator of Glutamate-gated Chloride Channels ( GluCls), which are crucial for nerve signaling in nematodes and arthropods. Its binding locks these channels open, triggering a massive, sustained influx of negatively charged chloride ions ( Cl^-) into the parasite's nerve and muscle cells.

Physiological Mechanism: Neuromuscular Paralysis

The resulting heavy influx of chloride ions causes immediate and severe hyperpolarization of the cell membranes, suppressing electrical excitability. This suppression results in flaccid paralysis of the body wall and inhibition of the pharyngeal pump (feeding mechanism), ultimately resulting in parasite death due to the functional inability to ingest nutrients or maintain motility.

Mechanistic Specificity and Host Protection

The mechanism demonstrates strong selectivity for invertebrates because of their specific GluCl architecture. In the mammalian host, P-glycoprotein (P-gp) efflux pumps actively transport Ivermectin out of the central nervous system (CNS), restricting its ability to engage host-equivalent receptors and minimizing engagement with host CNS targets.

The administration of the active ingredient, Ivermectin, is governed by standardized protocols established for medical use. These instructions outline the appropriate route, precise weight-based dosing, and required timing in relation to meals.

---

Official Administration Scope

Feature	Official Instruction / Rule
Route of administration	The approved route is Oral, typically using the tablet formulation standardized for human treatment.
Dosing schedule (for approved indications)	The standard regimen for Strongyloidiasis is a single oral dose providing 200 mu g/kg of body weight. For Onchocerciasis, the single dose is 150 mu g/kg of body weight.
Timing in relation to meals	Must be taken on an empty stomach with water. Food intake is restricted for two hours before and after administration to ensure proper absorption.
Age-group administration rules	Use is not established for children weighing less than 15 kg.

---

Official Administration Patterns

The frequency pattern is predominantly a Single Dose course for initial treatment. For Onchocerciasis, however, the administration may involve a Cyclic Retreatment pattern, with dosing repeated at intervals of 3 to 12 months to control microfilariae production. Specialized dosing rules, such as potential repeated courses, may apply to immunocompromised patients with strongyloidiasis.

The overall use protocol requires meticulous attention to these details. The medication's usage is defined by its precise weight-based calculation and the mandatory requirement for a fasting state. Additionally, for strongyloidiasis, clinical protocols specify that post-treatment stool examinations are a necessary procedural condition to confirm the clearance of the infection.

Evidence for Use in Strongyloidiasis (Intestinal Threadworm Infection)

Research involving Ivermectin was studied for the treatment of strongyloidiasis, a condition where threadworms infect the body. The evidence includes Randomized Controlled Trials (RCTs) and systematic reviews that explored outcomes related to physical discomfort and parasite clearance. Studies primarily monitored the parasitological cure rate (absence of the parasite in stool samples). Findings describe patterns observed in the studies where a measurable clearance was reported in the populations studied, often alongside monitored improvements in patient-reported symptoms like abdominal discomfort. However, long-term effects are not fully established regarding sustained clearance, and data for certain groups remain insufficient, particularly well-controlled studies for high-risk, immunocompromised patients.

---

Evidence for Use in Onchocerciasis (River Blindness)

Research was evaluated in large-scale Community Trials and extensive observational cohort studies. These studies examined outcomes reflecting daily functioning and parasite load in the skin and eyes. Community programs research describes a measurable reduction in microfilariae in the skin samples of monitored individuals. Long-term observational evidence data show patterns related to the development of severe visual impairment was observed less frequently in monitored communities. Findings indicate that research described the effect on the juvenile form of the parasite, and studies monitored outcomes was observed in programs that involve repeated, often annual, intervention over many years.

---

Research Limitations and Uncertainty

The research base includes extensive long-term follow-up for onchocerciasis, spanning many years. Research examined specific subgroups, including pediatric populations, based on criteria like height or weight. However, evidence quality varies across studies, and sample sizes were modest in some specific research exploring complicated presentations. There is limited information for long-term outcomes regarding the risk of the parasite developing reduced responsiveness, and subgroup findings are uncertain for specific co-infection contexts. The results apply only to the populations studied.

Key Studies & References

1. Ivermectin: MedlinePlus Drug Information

Common questions about Ivomec 0.27% (FAQ)

Q: What Ivomec 0.27% most commonly prescribed for in humans?

A: According to regulatory documents, the active ingredient Ivermectin in tablet form for human use is formally indicated for the treatment of two main parasitic infections: intestinal (nondisseminated) strongyloidiasis (threadworm infection) and onchocerciasis (river blindness).

Q: Does Ivomec 0.27% treat internal or external parasites, or both?

A: Official classifications categorize the active ingredient, Ivermectin, as a broad-spectrum antiparasitic agent, sometimes known as an endectocide. This signifies that it has activity against both internal parasitic worms (nematodes) and certain external arthropod parasites, depending on the species and indication.

Q: Is a headache a normal side effect when taking Ivomec 0.27%?

A: Studies and official safety information indicate that headache is a documented and commonly reported adverse reaction. While the occurrence varies by individual, it is one of the more frequent effects listed in regulatory documents.

Q: Does Ivomec 0.27% interact with common blood thinner medications?

A: Regulatory documents include warnings concerning co-administration with blood thinners. Specifically, there are post-marketing reports of an increased International Normalized Ratio (INR)—a measure of blood clotting time—when Ivermectin was taken alongside the anticoagulant warfarin.

Q: Is it safe to drink alcohol while being treated with Ivomec 0.27%?

A: Regulatory information indicates that the co-administration of ethanol (alcohol) may increase the drug's levels in the body or worsen certain side effects. Patients are advised to consult their healthcare provider regarding alcohol consumption during treatment.

Q: Are there known interactions between Ivomec 0.27% and herbal supplements?

A: Official drug information states that Ivermectin is metabolized primarily by the CYP3A4 enzyme in the liver. Since certain herbal supplements can influence this enzyme, potential interactions may exist. Patients are reminded to inform their healthcare provider about all medications and supplements they are taking.

Q: Why is it important to complete the full course of treatment with Ivomec 0.27%?

A: Official regulatory information emphasizes that for conditions like strongyloidiasis, repeated stool examinations are a necessary procedural step following treatment to document the clearance of the infection and to support the confirmation that the infection has been cleared.

Q: Does Ivomec 0.27% interfere with birth control or other hormonal medications?

A: Ivermectin is metabolized by the CYP3A4 enzyme, but it is not formally documented to significantly inhibit the activity of major CYP enzymes. Official labels do not specifically list interactions with hormonal birth control medications.

Q: Are there any signs of a serious allergic reaction to Ivomec 0.27% to watch out for?

A: Yes, official labeling notes that patients should watch for signs of a severe reaction, such as difficulty breathing, swelling of the face or eyelids, or a severe, peeling rash known as Stevens-Johnson syndrome. If symptoms of a serious reaction occur, immediate medical attention should be sought.

Q: What type of pre-screening is necessary before a doctor prescribes Ivomec 0.27%?

A: For individuals who have lived in or traveled through certain areas of Africa where the Loa loa parasite is common, official guidance advises that pretreatment assessment for loiasis is necessary. This is due to the increased risk of serious adverse events if co-infection is present.

Q: Is Ivomec 0.27% considered an anthelmintic medication?

A: Yes, Ivermectin, the active ingredient in the product, is officially classified by regulatory bodies as an Anthelmintic agent. This is the drug class used to treat parasitic worms (helminths).

Q: How long does the therapeutic effect of a single Ivomec 0.27% dose last?

A: For certain indications, such as onchocerciasis (river blindness), the official administration schedule requires retreatment at intervals ranging from 3 to 12 months. This suggests the sustained therapeutic effect of a single dose on the parasite's life cycle is limited.

Q: Is a follow-up visit or test usually required after taking Ivomec 0.27%?

A: Official prescribing information requires that patients treated for strongyloidiasis receive repeated stool examinations post-treatment. This is a crucial procedural condition to confirm that the infection has been successfully cleared.

Q: Why do some parasitic infections require repeat doses of Ivomec 0.27%?

A: For certain infections, like onchocerciasis, the medication is highly effective against the juvenile stage (microfilariae) but does not kill the adult parasites. Retreatment is part of the established protocol to manage the continuous production of new microfilariae by the remaining adult worms.

Q: Is a tingling sensation or dizziness normal after taking Ivomec 0.27%?

A: Regulatory documents list dizziness as a common adverse reaction, while a tingling sensation (paresthesia) is reported as a less common effect. Patients experiencing any unusual or severe symptoms should seek medical guidance.

Q: What should be done if a rash appears after taking Ivomec 0.27%?

A: If signs and symptoms of a Severe Cutaneous Adverse Reaction (SCAR), such as a serious, blistering rash, appear, official guidance states the medication should be withdrawn immediately. The patient should seek medical evaluation for a rash, as this may be a sign of a serious allergic response.

Q: Are there specific food items or drinks that should be avoided when taking Ivomec 0.27%?

A: Yes, official instructions mandate that the medication must be taken on an empty stomach with water, avoiding food two hours before and after the dose. This instruction is provided because food significantly increases the amount of drug absorbed into the body. Alcohol should also be avoided.

Q: Is Ivomec 0.27% the same medication as Stromectol?

A: Stromectol is the brand name for Ivermectin tablets that are formally approved by the FDA for human use. Ivomec 0.27% is a specific concentration of Ivermectin in a liquid formulation that is generally associated with veterinary products.

Q: Is Ivomec 0.27% an over-the-counter medicine or is a prescription required?

A: The formulation of Ivermectin approved for human use is a prescription-only medication in the United States and other regulated markets, marked with an 'Rx Only' designation.

Q: Can taking Ivomec 0.27% cause temporary vision changes or eye irritation?

A: Official adverse reaction lists include possible effects on the eyes, such as eye or eyelid irritation, pain, redness, or swelling. Less commonly, blurred vision has also been reported in clinical contexts.

Q: What is the role of ivermectin in the treatment of diseases like river blindness?

A: Ivermectin is formally indicated for treating onchocerciasis, commonly known as river blindness. Its role is to help manage the disease by reducing the number of juvenile parasites (microfilariae) in the skin and eyes, which are responsible for the disease’s complications.

Q: Has Ivomec 0.27% been studied in people with weakened immune systems?

A: Clinical studies have included a limited number of patients who are immunocompromised. For severe or disseminated strongyloidiasis in this group, official guidance indicates that special considerations for dosing may be part of the care plan for this group.

Q: Is Ivomec 0.27% effective against all types of parasitic worms?

A: No, Ivermectin is only active against certain life-cycle stages of specific parasites. For example, in onchocerciasis, it targets the microfilariae but is not active against the adult stage of the parasite.

Q: What kind of parasites is Ivomec 0.27% not effective against?

A: The drug is not universally effective against all parasites. Regulatory data confirms it is not active against the adult worm stage of Onchocerca volvulus, and its main activity in strongyloidiasis is limited to the intestinal stages.

Q: Does the efficacy of Ivomec 0.27% change depending on a person's weight?

A: Yes, official dosing is strictly determined by the patient's body weight to ensure the correct concentration of the drug reaches the system. This indicates that weight is a critical factor for achieving effective therapeutic drug levels.

Q: What does the body do to break down or metabolize Ivomec 0.27%?

A: Ivermectin is primarily metabolized, or broken down, in the liver by the CYP3A4 enzyme system. The drug itself and its metabolites are then excreted from the body almost entirely through the feces.

Q: Is it normal for certain symptoms to temporarily worsen after taking Ivomec 0.27%?

A: Yes, a documented set of symptoms known as the Mazzotti reaction may occur. This complex, which can include fever, itching, and joint pain, results from the body's reaction to the massive die-off of parasites and typically resolves within the first week of treatment.

Official Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of Ivomec (Ivermectin) solutions.

Category	Regulatory Requirement
Storage Temperature	Store at Controlled Room Temperature of 68^circmathrmF to 77^circmathrmF (20^circmathrmC to 25^circmathrmC). Excursions between 59^circmathrmF and 86^circmathrmF (15^circmathrmC to 30^circmathrmC) are permitted.
Container & Handling	The container must be kept tightly closed and stored in a well-ventilated area. The product is often labeled as FLAMMABLE and must be kept away from heat, sparks, open flame, and ignition sources. Avoid freezing.
Child Safety	Keep this and all drugs out of the reach of children. Safety Data Sheets recommend the product be stored locked up.
Disposal	Do not contaminate water by direct application or improper container disposal. The product is very toxic to aquatic life. Dispose of unused product, residual contents, and empty containers according to local regulatory requirements (e.g., approved landfill or incineration).

These guidelines ensure stability, prevent fire hazards due to the liquid's flammability, and protect the environment from contamination, as the active ingredient is hazardous to aquatic organisms.